Results 51 to 60 of about 77,108 (288)

Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab

OncoImmunology, 2018
Introduction: Checkpoint inhibitors, including the CTLA-4 blocking antibody ipilimumab, have become the new standard therapy for many metastatic cancers.
Anders H. Kverneland, Christian Enevold, Marco Donia, Lars Bastholt, Inge Marie Svane, Claus H. Nielsen   +5 more
doaj   +1 more source

European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma

ESMO Open, 2020
On the 15 November 2018, the Committee for Medicinal Products for Human Use adopted an extension to an existing indication for the use of nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for the first-line treatment of adult patients with ...
Jorge Camarero, Filip Josephson, Maja Sommerfelt Grønvold, Nikolaos Zafiropoulos, Sahra Ali, Paula van Hennik, Christian Syvertsen, Bjorn Oddvar Strøm, Mats Ökvist, Brigitte Keller-Stanislawski, Elias Pean, Silvy da Rocha Dias, Franscesco Pignatti   +12 more
doaj   +1 more source

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

Frontiers in Pharmacology, 2021
Objective: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab vs. chemotherapy in the first-line setting for patients with advanced non-small-cell lung cancer (NSCLC) from the US payer perspective.Materials and methods: A Markov ...
Xiaomin Wan, Xiaohui Zeng, Liubao Peng, Ye Peng, Qiao Liu, Lidan Yi, Xia Luo, Qijian Deng, Qijian Deng, Chongqing Tan   +9 more
doaj   +1 more source

Biology of advanced uveal melanoma and next steps for clinical therapeutics [PDF]

, 2014
Uveal melanoma is the most common intraocular malignancy although it is a rare subset of all melanomas. Uveal melanoma has distinct biology relative to cutaneous melanoma, with widely divergent patient outcomes.
Bastian, BC, Bowcock, AM, Carvajal, RD, Flaherty, KT, Gershenwald, JE, Gutkind, JS, Luke, JJ, McKenna, KC, Patel, PM, Sato, T, Selig, S, Sossman, JA, Streicher, HZ, Sznol, M, Thurin, M, Triozzi, PL, Van Meir, EG, Welch, J   +17 more
core   +1 more source

Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies

Molecular Oncology, EarlyView.
We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck, Nele De Meulenaere, Thomas Vanpoucke, Joe Ibrahim, Dieter Peeters, Suresh Krishan Yogeswaran, Wen Wen, Paul Van Schil, Jeroen M. H. Hendriks, Jo Raskin, Jan van Meerbeeck, Guy Van Camp, Ken Op de Beeck   +12 more
wiley   +1 more source

Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod

Case Reports in Oncology, 2018
Simultaneous or sequential, planned administration of ipilimumab could significantly enhance the antitumor effects of nivolumab in advanced melanoma patients.
Taku Fujimura, Yumi Kambayashi, Yota Sato, Kayo Tanita, Sadanori Furudate, Akira Tsukada, Hisayuki Tono, Akira Hashimoto, Setsuya Aiba   +8 more
doaj   +1 more source

Toxic Epidermal Necrolysis During Cotherapy with Ipilimumab and Nivolumab [PDF]

Journal of Immunotherapy and Precision Oncology, 2018
Ipilimumab and nivolumab are human monoclonal antibodies used in cancer therapy. Ipilimumab targets cytotoxic T-lymphocyte-associated antigen and nivolumab acts against programmed death receptor-1. Both drugs have extensive side effect profiles with high
Shelby L Kubicki, Macartney E Welborn, Anisha B Patel   +2 more
doaj   +1 more source

The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma [PDF]

, 2015
The melanoma-specific graded prognostic assessment (msGPA) assigns patients with brain metastases from malignant melanoma to 1 of 4 prognostic groups.
A Likhacheva, A Snyder, Adam Bloomfield, AM Broadbent, Andrew Furness, Anna Wilkins, C Nieder, C Nieder, D Mathieu, D Rades, E Weltman, FE Harrell Jr, GV Long, J Larkin, J Lorenzoni, J Raizer, James Larkin, JG Lorenzoni, K Margolin, Kevin Harrington, LE Gaspar, M Staudt, MA Hofmann, Nuria Porta, P Royston, PC Tumeh, PW Sperduto, PW Sperduto, R Dummer, R Fisher, R Partl, Richard W Corbett, SL Morris, Stephen Morris, T Serizawa, TK Eigentler, Zohra Ali   +36 more
core   +2 more sources

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma

Journal for ImmunoTherapy of Cancer, 2020
Background A synergy between radiotherapy and anti-cytotoxic-T-lymphocyte-associated antigen 4 (anti-CTLA-4) monoclonal antibody has been demonstrated preclinically.
Caroline Robert, Christine Mateus, Christophe Massard, Roger Sun, Eric Deutsch, Lydie Cassard, Rastilav Bahleda, Severine Roy, Emilie Routier, Nathalie Chaput-Gras, Caroline Caramella, Emilie Lanoy, Alicia Larive, Yun Gan Tao, Dominique Schwob, Nathalie Ibrahim, Rita Maria Khoury Abboud, J -C Soria   +17 more
doaj   +1 more source